Hosanna Clay
Payments from drug & device makers
Across 142 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$554
- Xeris Pharmaceuticals, Inc.$331
- Insulet Corporation$249
- Novartis$240
- Lilly USA, LLC$219
- Sanofi-aventis U.S. LLC$214
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,317100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 25 | $554 |
| Xeris Pharmaceuticals, Inc. | 16 | $331 |
| Insulet Corporation | 2 | $249 |
| Novartis | 13 | $240 |
| Lilly USA, LLC | 10 | $219 |
| Sanofi-aventis U.S. LLC | 10 | $214 |
| Chiesi USA, Inc. | 8 | $176 |
| BETA Bionics, Inc. | 5 | $150 |
| Novo Nordisk | 3 | $130 |
| Dexcom, Inc. | 2 | $126 |
| Tandem Diabetes Care, Inc. | 5 | $105 |
| Antares Pharma, Inc. | 4 | $87 |
| Ascensia Diabetes Care US Inc. | 5 | $85 |
| Recordati_rare_diseases_inc. | 4 | $73 |
| Boehringer Ingelheim | 3 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $61 |
| Medtronic | 3 | $59 |
| Boston Scientific | 2 | $50 |
| Madrigal Pharmaceuticals | 2 | $40 |
| Amryt Pharma Holdings Ltd | 2 | $37 |
| AbbVie | 2 | $31 |
| Radius Health, Inc. | 2 | $30 |
| RGH Enterprises LLC | 1 | $25 |
| Sandoz | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Rhythm Pharmaceuticals, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $19 |
| Esteve Pharmaceuticals LLC | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Amphastar Pharmaceuticals, Inc. | 1 | $13 |
| Cequr Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$249
- EVENITY$122
- DEXCOM G7 GSS (161)$108
How this compares
$3,317 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $47,352 |
| TrulicityDulaglutide | 16 | $31,757 |
| JardianceEmpagliflozin | 23 | $29,607 |
| OzempicSemaglutide | 12 | $21,976 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $20,161 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $15,938 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $14,888 |
| FarxigaDapagliflozin Propanediol | 12 | $12,734 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $12,380 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $9,769 |
| TradjentaLinagliptin | 12 | $6,203 |
| Testosterone | 15 | $4,908 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,402 |
| Levothyroxine Sodium | 38 | $829 |
| Ezetimibe | 14 | $696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $219 | $79,10951 claims |
| Boehringer IngelheimJardiance, Tradjenta | $66 | $35,81035 claims |
| Novo NordiskOzempic | $130 | $21,97612 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $214 | $15,93820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.
Other family in Sandy
- Riley WorthSandy$1.1M
- Shelby MillerSandy$140K
- John MooreSandy$21K
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.